Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The global sepsis market has been valued at $3.48 billion in 2020 and is expected to grow at a CAGR of more than 7.5% across the seven major pharmaceutical markets (7MM) the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan during the forecast period. As of 2020, the market has been dominated by antibiotics and supportive therapies for the treatment of sepsis, most of which are available as generic versions. Due to its high diagnosed incidence rate of sepsis, the US market constitutes more than 69% of the 7MM sepsis market in 2020.

The growth in the sepsis market is being driven by the projected increase in sepsis and the launch of new therapies. While the 7MM population is expected to increase by more than 2% during the forecast period, the number of sepsis and septic shock incident cases is also expected to increase. This market growth is expected to be due to improved sepsis diagnostic abilities, and by the anticipated launch of new sepsis therapeutics with novel mechanisms of action (MOAs), such as monoclonal antibodies, recombinant proteins, and synthetic peptides, during the forecast period. Current clinical trials of these new agents suggest that they will supplement existing antibiotic therapies while replacing existing supportive therapies.

Overview of the Sepsis market

Overview of the Sepsis market

For more insights on this report, download a free report sample

What are the market dynamics and market barriers for the Sepsis market?

The major drivers of the growth within the sepsis market includes the launch of four new pipeline drugs: adrecizumab, Motrem, recap, and CYT107, and an increased prevalence of sepsis and septic shock across the 7MM that together with improved awareness of sepsis, will result in a larger treated patient population.

Also, with this, the major barriers to the growth of the market include, the high cost of the biologics that are likely to represent a major barrier for physicians prescribing these medications, the complexity inherent to multiple organ involvement in sepsis and septic shock continues to hinder the development of safe and tolerable agents that are effective at treating all manifestations of sepsis,  the randomized controlled trials (RCTs) will assist in reducing the heterogeneity observed in these trials, and the impact of the COVID-19 pandemic has thus resulted in serious delays of clinical trials for the sepsis pipeline therapeutics.

What is the country-based Sepsis market trends?

In the 7MM, the US had the highest diagnosed incidence of sepsis in 2020, and the UK had the lowest diagnosed incidence in 2020. The rate of increase was found to be highest in the US, rising from 306.81 cases per 100,000 population in 2010 to 492.47 cases per 100,000 population in 2020. The UK had the lowest rate of increase in incidence from 2010–2020. This increase is driven by the growing aging population and the rising incidence of comorbidities in the affected population.

In the 7MM, the US had the highest diagnosed incidence of septic shock in 2020 (99.46 cases per 100,000 population), and the UK had the lowest diagnosed incidence in 2020 (19.51 cases per 100,000 population). The rate of increase was highest in the US, rising from 63.47 cases per 100,000 population in 2010 to 99.46 cases per 100,000 population in 2020. The UK had the lowest rate of increase in incidence from 2010–2020.

Diagnosed incidence of Sepsis, cases per 100,000 population

Diagnosed incidence of Sepsis, cases per 100,000 population

For more insights, download a free report sample

How has the global COVID-19 pandemic impacted the Sepsis market?

The COVID-19 pandemic has directly impacted several clinical trials in the sepsis therapy area. However, many companies in the sepsis therapeutic area have a unique position in the pharmaceutical market, as they can benefit from the COVID-19 situation. Many pipelines and marketed sepsis drugs are currently enrolled in various clinical trials to treat COVID-19. Inotrem announced in July 2021 that it has obtained authorization to pursue the clinical development of Motrem in COVID-19 patients from both the French and Belgian competent authorities.

AM-Pharma was also engaged in Phase III clinical trial testing recAP on COVID-19 patients with SA-AKI. It is unknown whether the COVID-19 clinical trials will have an impact on the duration and/or success of the sepsis trials, such as if the COVID-19 trials are prioritized or receive extra resources at the expense of clinical trials for patients with sepsis.

What are the disease management and treatment overview for Sepsis?

Antibiotics are found to be the mainstay of treatment for sepsis because most causative infections result from bacterial colonization. Antibiotics have been shown to significantly decrease mortality when they are given within an hour of diagnosis of sepsis, compared to after an hour.

If sepsis is caused by a virus, fungus, or parasite, then the use of antivirals, antifungals, and antiparasitic, respectively, will become a critical component of disease management for the affected patient. The other treatments include fluid therapies, vasopressor, anticoagulant, immunomodulator and medical devices.

What are the key players in the Sepsis market?

As of August 2021, there were more than 270 companies developing drug candidates for the treatment of sepsis in the 7MM. Some of the major players involved are Adrenomed A.G., AM-Pharma B.V., Asahi Kasei Pharma, Grifols, Inotrem, La Jolla, Merck, Pfizer, Sanofi and RevImmune.

Sepsis market, by key players

Sepsis market, by key players

For more insights, download a free report sample

Market report scope

Market size of profit sector

(Year – 2020)

$3.48 billion
Growth rate of profit sector CAGR of >7.5% from 2021 to 2025
Base year for estimation 2020
Market segments by country The US, France, Germany, Italy, Spain, the UK, and Japan
Forecast period 2021–2025
Key players Adrenomed A.G., AM-Pharma B.V., Asahi Kasei Pharma, Grifols, Inotrem, La Jolla, Merck, Pfizer, Sanofi and RevImmune.

Scope

This report provides a comprehensive analysis of the Sepsis market- 

  • Overview of sepsis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline sepsis therapeutics market revenue from 2020–2030. The annual cost of therapy and major pipeline product sales in this forecast period are included.
  • Key topics covered include current sepsis therapies, unmet needs and opportunities, and the drivers and barriers affecting treatment sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global sepsis therapeutic market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global sepsis therapeutic market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Adrenomed
AM-Pharma
Asahi Kasei
Grifols
Inotrem
La Jolla
Merck
Pfizer
Sanofi
Takeda

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Sepsis: Executive Summary

1.1 Sepsis Treatment to Experience Strong Growth over the Forecast Period from 2020–2030

1.2 Developers Must Leverage Innovative R&D Strategies to Target Appropriate Patients and Achieve Sustained Commercial Success

1.3 A High Level of Unmet Need Persists in the Sepsis and Septic Shock Marketplace

1.4 Opportunities Remain for Current and Future Players to Develop Therapies Targeting Sepsis-Specific Pathophysiology

1.5 Immunomodulating Therapies Poised to Transform Sepsis and Septic Shock Market, but Missing Biomarkers Will Limit Their Utility

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.4.3 Diagnosed Incident Cases of Sepsis

4.4.4 Diagnosed Incident Cases of Sepsis by Causative Agent

4.4.5 Organ Dysfunction in Diagnosed Incident Cases of Sepsis

4.4.6 Sepsis In-Hospital Mortality Cases

4.4.7 Diagnosed Incident Cases of Septic Shock

4.4.8 Diagnosed Incident Cases of Septic Shock by Causative Agent

4.4.9 Organ Dysfunction in Diagnosed Incident Cases of Septic Shock

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 Treatment Guidelines

5.3 Clinical Management of Sepsis

5.3.1 Systemic Inflammatory Response Syndrome

5.3.2 Sepsis

5.3.3 Septic Shock

5.3.4 Multiple Organ Dysfunction Syndrome

5.3.5 Nosocomial Sepsis: Healthcare-Associated and Hospital-Acquired

5.3.6 Neonatal Sepsis

5.4 Marketed Drugs by Therapeutic Class

5.4.1 Antibiotics

5.4.2 Other Anti-infective Agents

5.4.3 Vasopressors and Inotropes

5.4.4 Anticoagulants

5.4.5 Immunomodulators

5.5 Non-pharmacotherapeutic Measures for the Treatment of Sepsis

5.5.1 Mechanical Ventilation

5.5.2 Hemodialysis

5.5.3 Fluid Resuscitation

5.5.4 Blood Product Administration

5.5.5 Nutritional Accommodations for Septic Patients

5.6 Treatment of Sepsis by Geographic Region

5.6.1 US

5.6.2 5EU

5.6.3 Japan

5.7 Key Opinion Leader Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Sepsis Education and Awareness for the Public and Healthcare Professionals

7.3 Early Recognition and Treatment of Sepsis

7.4 Improved Supportive Care for Sepsis-Induced Comorbidities

7.5 Improved Understanding of Sepsis Pathophysiology

8 R&D Strategies

8.1 Overview

8.2 Development of Sepsis Therapeutics with Diverse Mechanisms of Action

8.2.1 Coagulation System

8.2.2 Endothelium

8.2.3 Organ Damage

8.2.4 Host Immune Response

8.3 Label Expansion of Existing Marketed Drugs for Similar Indications

8.4 Collaboration, Licensing, and Partnerships

8.5 Clinical Trial Design

8.5.1 Current Clinical Trial Designs for Sepsis Drug Candidates

8.5.2 Issues with Current Clinical Trial Design for Sepsis Drug Candidates

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Clinical Trials

9.4 Early-Stage Pipeline Agents

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Clinical Benchmark of Key Pipeline Drugs

10.2.1 Clinical Benchmarking of Immunomodulators

10.2.2 Clinical Benchmarking of Vasopressors

10.2.3 Clinical Benchmarking of Antimicrobials

10.2.4 Clinical Benchmarking of Fluid Therapy

10.3 Commercial Benchmark of Key Pipeline Drugs

10.3.1 Commercial Benchmarking of Immunomodulators

10.3.2 Commercial Benchmarking of Vasopressors

10.3.3 Commercial Benchmarking of Antimicrobials

10.3.4 Commercial Benchmarking of Fluid Therapies

10.4 Competitive Assessment

10.4.1 Competitive Assessment of Immunomodulators

10.4.2 Competitive Assessment of Vasopressors

10.4.3 Competitive Assessment of Antimicrobials

10.4.4 Competitive Assessment of Fluid Therapy

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

11.3 Adrenomed

11.3.1 Overview

11.3.2 Portfolio Assessment

11.4 AM-Pharma

11.4.1 Overview

11.4.2 Portfolio Assessment

11.5 Asahi Kasei Pharma

11.5.1 Overview

11.5.2 Portfolio Assessment

11.6 Grifols

11.6.1 Overview

11.6.2 Portfolio Assessment

11.7 Inotrem

11.7.1 Overview

11.7.2 Portfolio Assessment

11.8 La Jolla

11.8.1 Overview

11.8.2 Portfolio Assessment

11.9 Merck

11.9.1 Overview

11.9.2 Portfolio Assessment

11.10 Pfizer

11.10.1 Overview

11.10.2 Portfolio Assessment

11.11 RevImmune

11.11.1 Overview

11.11.2 Portfolio Assessment

11.12 Sanofi

11.12.1 Overview

11.12.2 Portfolio Assessment

11.13 Takeda

11.13.1 Overview

11.13.2 Portfolio Assessment

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.3.2 Diagnosed Sepsis and Septic Shock Patients

13.3.3 Percent Drug-Treated Patients

13.3.4 Drugs Included in Each Therapeutic Class

13.3.5 Launch and Patent Expiry Dates

13.3.6 General Pricing Assumptions

13.3.7 Individual Drug Assumptions

13.3.8 Generic Erosion

13.3.9 Pricing of Pipeline Agents

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Global Director of Therapy Analysis and Epidemiology

13.6.5 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Sepsis: Key Metrics in the 7MM

Table 2: Stages of Sepsis, According to SSC Guidelines

Table 3: Risk Factors and Comorbidities for Sepsis and Septic Shock

Table 4: Criteria Used for SOFA Score in the Diagnosis of Sepsis

Table 5: Treatment Guidelines for Sepsis in the 7MM

Table 6: Commonly Used Antibiotics in Sepsis and Septic Shock and Corresponding Gaps in Coverage

Table 7: Examples of Supportive Therapies for Patients with Sepsis or Septic Shock

Table 8: Sepsis Disease Management – US

Table 9: Sepsis Disease Management – 5EU

Table 10: Sepsis Disease Management – Japan

Table 11: Marketed Therapies for Sepsis Across the 7MM

Table 12: Collaboration, Licensing and Deals of Sepsis Drug Candidates

Table 13: Clinical Trial Designs for Sepsis Pipeline Drug Candidates

Table 14: Innovative Early-Stage Approaches for Sepsis, 2021

Table 15: Clinical Benchmark of Key Marketed and Pipeline Drugs – Immunomodulators in Sepsis

Table 16: Clinical Benchmark of Key Marketed and Pipeline Drugs – Vasopressors in Sepsis

Table 17: Clinical Benchmark of Key Marketed and Pipeline Drugs – Antimicrobials in Sepsis

Table 18: Clinical Benchmark of Key Marketed and Pipeline Drugs – Fluid Therapy in Sepsis

Table 19: Commercial Benchmark of Key Marketed and Pipeline Drugs – Immunomodulators in Sepsis

Table 20: Commercial Benchmark of Key Marketed and Pipeline Drugs – Vasopressors in Sepsis

Table 21: Commercial Benchmark of Key Marketed and Pipeline Drugs – Antimicrobials in Sepsis

Table 22: Commercial Benchmark of Key Marketed and Pipeline Drugs – Fluid Therapy in Sepsis

Table 23: Adrenomed’s Sepsis Portfolio Assessment, 2021

Table 24: AM-Pharma’s Sepsis Portfolio Assessment, 2021

Table 25: Asahi Kasei Pharma’s Sepsis Portfolio Assessment, 2021

Table 26: Grifols’ Sepsis Portfolio Assessment, 2021

Table 27: Inotrem’s Sepsis Portfolio Assessment, 2021

Table 28: La Jolla’s Sepsis Portfolio Assessment, 2021

Table 29: Merck’s Sepsis Portfolio Assessment, 2021

Table 30: Pfizer’s Sepsis Portfolio Assessment, 2021

Table 31: RevImmune’s Sepsis Portfolio Assessment, 2021

Table 32: Sanofi’s Sepsis Portfolio Assessment, 2021

Table 33: Takeda’s Sepsis Portfolio Assessment, 2021

Table 34: Sepsis Market – Global Drivers and Barriers, 2020–2030

Table 35: Key Events Impacting Sales for Sepsis in the US, 2020–2030

Table 36: Sepsis Market – Drivers and Barriers in the US, 2020–2030

Table 37: Key Events Impacting Sales for Sepsis in the 5EU, 2020–2030

Table 38: Sepsis Market – Drivers and Barriers in the 5EU, 2020–2030

Table 39: Key Events Impacting Sales for Sepsis in Japan, 2020–2030

Table 40: Sepsis Market – Drivers and Barriers in Japan, 2020–2030

Table 41: Key Projected Launch Dates for Sepsis and Septic Shock

Table 42: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Sepsis in 2020 and 2030

Figure 2: Company Portfolio Gap Analysis in Sepsis During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Sepsis During the Forecast Period

Figure 4: Pathophysiological Features of Sepsis

Figure 5: 7MM, Diagnosed Incidence of Sepsis, All Ages, Men and Women, Cases per 100,000 Population, 2010‒2030

Figure 6: 7MM, Diagnosed Incidence of Septic Shock, All Ages, Men and Women, Cases per 100,000 Population, 2010‒2030

Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Incident Cases of Sepsis

Figure 8: 7MM, Sources Used for the Diagnosed Incident Cases of Septic Shock

Figure 9: 7MM, Sources Used for the Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agents

Figure 10: 7MM, Sources Used for Organ Dysfunction in the Diagnosed Incident Cases of Sepsis

Figure 11: 7MM, Sources Used for Organ Dysfunction in the Diagnosed Incident Cases of Septic Shock

Figure 12: 7MM, Sources Used and Not Used for Sepsis/Septic Shock In-Hospital Mortality Cases

Figure 13: Overview of Treatment Options for Sepsis and Septic Shock

Figure 14: Unmet Needs and Opportunities in Sepsis and Septic Shock

Figure 15: Overview of the Global Development Pipeline in Sepsis

Figure 16: Key Clinical Trials for Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Sepsis During the Forecast Period

Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Sepsis During the Forecast Period

Figure 18: Competitive Assessment of RecAP and CYT107, the Pipeline Therapies for Immunomodulation in Sepsis, Benchmarked against the SOCs, Hydrocortisone and IVIg

Figure 19: Competitive Assessment of Motrem and Adrecizumab, the Pipeline Therapies for Vasopressors in Sepsis, Benchmarked against the SOC, Norepinephrine

Figure 20: Competitive Assessment of Cefiderocol, the Pipeline Therapy for Antimicrobials in Sepsis, Benchmarked against the SOC, Meropenem

Figure 21: Competitive Assessment of Human Albumin, the Pipeline Therapy for Fluid Therapy in Sepsis, Benchmarked against the SOC, Ringer’s lactate

Figure 22: Company Portfolio Gap Analysis in Sepsis, 2020–2030

Figure 23: Global (7MM) Sales Forecast by Country for Sepsis in 2020 and 2030

Figure 24: Sales Forecast by Class for Sepsis in the US in 2020 and 2030

Figure 25: Sales Forecast by Class for Sepsis in the 5EU in 2020 and 2030

Figure 26: Sales Forecast by Class for Sepsis in Japan in 2020 and 2030

Frequently asked questions

Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Insulin Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030 in real time.

  • Access a live Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.